Jos Melenhorst
@jj-melenhorst.bsky.social
Translational immunologist and immunogene therapy developer at Cleveland Clinic. Passionate about biomarker discovery, mechanistic studies, and advancing cellular therapies to improve cancer treatment every day.
How is Bluesky different from Twitter again..🤔
March 14, 2025 at 3:00 AM
How is Bluesky different from Twitter again..🤔
Reposted by Jos Melenhorst
Unproven and unregulated don't go well together - QC Kinetix review: concerns on huge regenerative clinic chain h/t @stemcells.bsky.social ipscell.com/2024/12/qc-k...
QC Kinetix review: concerns on huge regenerative clinic chain - The Niche
Professor reviews QC Kinetix and goes through what he sees as several red flags with this large unproven regenerative clinic chain.
ipscell.com
December 16, 2024 at 1:24 PM
Unproven and unregulated don't go well together - QC Kinetix review: concerns on huge regenerative clinic chain h/t @stemcells.bsky.social ipscell.com/2024/12/qc-k...
Me at a slightly younger age playing slide guitar with a beer bottle. I thought it sounded great 🤪
November 23, 2024 at 11:47 PM
Me at a slightly younger age playing slide guitar with a beer bottle. I thought it sounded great 🤪
Lovely, how this community builds..
November 19, 2024 at 4:31 AM
Lovely, how this community builds..
Somebody please tell SITC, ASH, AACR about this cool new place! And of course all cancer immunologists and immunotherapists (my crowd 😉)
November 19, 2024 at 12:14 AM
Somebody please tell SITC, ASH, AACR about this cool new place! And of course all cancer immunologists and immunotherapists (my crowd 😉)
I am new to this platform. Is there anyone from the cancer immunology, immunotherapy fields on Bluesky?
November 18, 2024 at 6:36 PM
I am new to this platform. Is there anyone from the cancer immunology, immunotherapy fields on Bluesky?